Search TNDM
TANDEM DIABETES CARE INC
Nasdaq · CIK 1438133
Last close16.5
Daily change+0.00 (0.00%)
10 Years gain-78.32%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
TNDM · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
47.6Momentum
100.0Acceleration
100.0Confidence
91.0Annual Revenue14
Quarterly Revenue67
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth8.4 / 25
Quality17.6 / 25
Capital Efficiency5.8 / 20
Balance Sheet10.8 / 15
Shareholder Economics5.1 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 3.4655 percentage points.
Operating leverageOperating margin improved by 15.5046 percentage points.
ROIC expansionROIC improved by 104.9148 percentage points.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Key Metrics
Revenue Growth TTM3.96%OK
Revenue CAGR 3Y8.19%OK
Gross Margin56.01%OK
Operating Margin-4.4%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-17.91%OK
Incremental Operating Margin 3Y19.59%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y2.92%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $1.01B | $546.01M | -$187.26M | -$9.72M | -$29.67M | 53.81% | -18.45% | -2.92% | -85.45% | 67.29M |
| 2025 FY Dec 31, 2024 | $940.20M | $489.57M | -$99.13M | $24.23M | $4.99M | 52.07% | -10.54% | 0.53% | -51.44% | 65.45M |
| 2025 FY Dec 31, 2023 | $747.72M | $367.69M | -$233.23M | -$31.81M | -$58.61M | 49.18% | -31.19% | -7.84% | n/a | 64.97M |
| 2024 FY Dec 31, 2022 | $801.22M | $412.99M | -$92.85M | $50.46M | $16.37M | 51.54% | -11.59% | 2.04% | n/a | 64.15M |
| 2023 FY Dec 31, 2021 | $702.80M | $376.22M | $22.65M | $111.36M | $97.18M | 53.53% | 3.22% | 13.83% | n/a | 64.35M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.04B | sum latest 4 fiscal quarters Revenue | OK | 0001438133-25-000187, 0001438133-26-000010 |
| Revenue Growth TTM | 3.96% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001438133-25-000187, 0001438133-26-000010 |
| Revenue CAGR 3Y | 8.19% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001438133-26-000010 |
| Revenue CAGR 5Y | 15.26% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001438133-26-000010 |
| Gross Profit CAGR 3Y | 9.75% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001438133-26-000010 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001438133-25-000187, 0001438133-26-000010 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 56.01% | Gross Profit / Revenue | OK | 0001438133-25-000187, 0001438133-26-000010 |
| Operating Margin | -4.4% | Operating Income / Revenue | OK | 0001438133-25-000187, 0001438133-26-000010 |
| ROIC | -17.91% | NOPAT / Average Invested Capital | OK | 0001438133-25-000187, 0001438133-26-000010 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001438133-26-000125 |
| Current Ratio | 3.18x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.76x | (Cash + Short-term Investments) / Total Debt | OK | 0001438133-26-000125 |
| Revenue per Diluted Share | $15.09 | Revenue / Diluted Shares | OK | 0001438133-25-000187, 0001438133-26-000010 |